Member Info for bigAl67

You are pretty well correct Raffs - starres posted circa 140 de-ramp GDR posts after posting this :-

'I did reduce a lot. sorry, do I sound too negative (honest)?' - Posted by starres on the 8th April 2023.

- so starres ? questioned his 'own Honesty' then, and had been posting many negative GDR posts before this post on the 8th April. - seems to me there is a link between 'De-rampers and a lack of Honesty' IMHO

Ref: Votes to be cast for the resolutions of the forthcoming meeting by 2pm on Friday 5th May.

On the ii Platform click on the 'Portfolio' Heading, and then on 'Voting mailbox' - takes you to your ii accounts with the action to vote.

@Carlose,
In my post I included the points I dis-agreed with, and why I dis-agreed with them – You appear to have not read or have not understood this OR deliberately ignored it, such is your Bitterness???
I see that amongst the Many Posters you have slated over your entire history of Posting is your ****ging off of starres, and you conveniently missed his name out in your Bitter post to me – Now why would that be I wonder? – Deliberate I reckon, after all how could you attack me for mentioning starres, when you have attacked his Posts many times more severely than I - says it all about you Really.

Going Fishing for the day - Please try hard to be a 'NICE' Boy while I am away LOL

Just had a quick check out of your last 40 Posts Carlose666, and everyone of them are Bitter, Nasty attacks on Posters - My guess is that if I checked the next Forty Posts, the Facts would be the same and speak for themselves about the type of Character you are.

I have no problem with anyone checking out my Posting History Carlose - they will see constructive Posts - unlike yourself - It would be funny if your Bitter attacks were not so Nasty.

Just check out Carlose666 Posting History Everyone - Click on his Posting Name, see his History for yourselves, and make your own Minds up, about the sort of Person Carlose is ????

LOL - Look who has dropped in with his usual attacks on Posters.....It's...... Carlose666.

Click on his Posting name and ''Check Out His History;;, by a Massive Majority his posts are attacks on Posters - This Guy must be a Bundle of Fun to Live with - A Very Sad, Bitter and Twisted Individual.
He has never posted any evidence of his accusations, and when I asked for his evidence he ran off with his Tail between his Legs - typical of a Sad, Bitter and Twisted Individual - He has mates on here too LOL

Laughable - the starres and stockp*ick duo:-
stockp*ick posted that the USA market would be transformational, and ignores the fact that Europe is just as Transformational, and that we can sell into Europe without the costs involved in selling into the USA 'right now'!!
AIHL Potential:-
. UK market potential of £8.5 million per annum
. Europe market potential of £35 million per annum (Increasing Distributer agreements in Europe.)
. USA market potential of £35 million per annum

stockp*ick does not even know the nationality of our CEO, but chooses to say that he is American, and then conclude from his wrongful guess - ' You’d think he would be on top of the mechanics of dealing with a Federal US regulatory system'. - well David Budd is Not American.

My retort to his USA submission comment is:- 'It doesn’t take a rocket scientist to work out that news of sales into Europe would provide jet propulsion to the share price - and the USA submission will follow!!

As David Budd said (On the 31st March), with reference to the £2,000,000 pre payment from RF:-
'The Company is not currently planning for a material increase in the Company's operating expenses in the future and the Company's pro forma cash balances post receipt of the Initial Prepayment alone will be circa £3.5 million. This will provide the Company with additional capital to drive sales of its AIHL assay and finalise the development/plan for launch of its CYP2C19 assay which are both expected to be key potential drivers of shareholder value in the future.'

Agreed Johnlay,

This the latest stated from GDR on the 31st March 2023:-
A pre-submission (Pre-Sub) was filed with the FDA to agree the regulatory approval process of the Genedrive® MT-RNR1 ID Kit into the USA. The Pre-Sub process allows the Company an opportunity to clarify its testing and validation approach, confirm the appropriate regulatory application pathway, which are uncertain given that there is no directly comparable test in the market. The Company is in ongoing dialogue still with the FDA to ascertain the requirements, and consequently the funding estimate that would be required to conduct and manage the evidence generation and submission process.

Reference: Genedrive PLC Final Results Presentation through the Investors Meet Company webinar on the 21st November 2022.
10 minutes into the Genedrive PLC Presentation (Bottom of Slide 5), David Budd said:-
Most recently we filed with the US FDA our Pre-submission for the MTRN1 Kit. We previously indicated that we planned to wait for sufficient funding to be in place in order to pay for the entire FDA process. But We have now identified some Partners in the USA that can support us to make the overall process more cost effective !
Our FDA Pre-sub is really just a first phase to get agreement from the FDA on the clinical and study approaches of our registration process, given the unique nature of our MTRN1 Product.

Hi stephen11,

Our Day Will Come For Sure, and Then we will gain GDR's real Potential !!

Hi System,
It is very clear that it is £100 million equally shared be tween the 3 off clusters, whereby Greater Manchester receives £33 million over a 2 year programme!!

20March2023
Greater Manchester secures multi-million investment to improve the diagnosis and treatment of disease to save more lives
Greater Manchester health and care partners, in collaboration with academia and industry, today (16 March 2023) announce the launch of a new multi-million pound health innovation accelerator focused on rapidly improving the diagnosis and treatment of disease across the 2.8m GM population.

Government is investing £100 million to accelerate the growth of three high-potential innovation clusters, Glasgow, Greater Manchester, and the West Midlands. This investment will ensure they become major, globally competitive, centres for research and innovation.

As part of a two-year programme, Greater Manchester will launch innovative projects in sectors where it has existing research strengths, including advanced materials, artificial intelligence (AI), diagnostics, and net zero.
The health innovation accelerator will focus on tackling some of the most challenging disease areas through early diagnosis using novel approaches and holistic treatment aligned to people’s specific needs. It is hoped this will help to save more lives and improve health outcomes for people at high risk or living in the most disadvantaged communities.

The health accelerator will focus on enhanced diagnostics and genomics, delivered through a partnership between Health Innovation Manchester, Manchester University NHS Foundation Trust, and the University of Manchester.

Further significant investment has also been leveraged through partnerships with businesses in life sciences, digital and creative industries, which is a testament to the strength of Greater Manchester’s partnerships with industry.

Bill Newman, Professor of Translational Genomic Medicine at UoM, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.”

£100m Innovation Accelerator Program provides £33m each to 3 emerging clusters

Three city regions in Glasgow, Greater Manchester and West Midlands were chosen to pilot this programme in recognition of their R&D strengths, robust private and public innovation governance and strong local leadership.

The £100 million funding is being shared across those three regions and has been allocated using a pioneering ‘locally-led’ approach.

The projects will address local, national and global societal and environmental challenges. They range from developing health innovations to quantum technologies, and green technologies to secure a safe and resilient transition to net zero.

Greater Manchester will lead the way in sustainable advanced materials and manufacturing, digital and tech, health innovation, and technology to become carbon neutral by 2038.

Record investment in our UK science, technology and innovation sectors are creating new career opportunities in the campuses, clusters and companies of tomorrow.

R&D is key to levelling-up by growing the R&D Innovation Economy outside the Greater South East.

That’s why UKRI is putting clusters at the heart of its strategy and why our £100m Innovation Accelerator Program provides £33m each to 3 emerging clusters to attract industrial co-investment and become major, globally competitive centres.

Record investment in our UK science, technology and innovation sectors are creating new career opportunities in the campuses, clusters and companies of tomorrow.

R&D is key to levelling-up by growing the R&D Innovation Economy outside the Greater South East.

That’s why UKRI is putting clusters at the heart of its strategy and why our £100m Innovation Accelerator Program provides £33m each to 3 emerging clusters to attract industrial co-investment and become major, globally competitive centres.

Mayor of Greater Manchester, Andy Burnham, said:

Greater Manchester’s selection as one of three Innovation Accelerator regions reflects the high level of confidence in our innovation ecosystem.

The projects being backed are undertaking world-leading research to address some of the biggest challenges we face.

They also align with the sectors where Greater Manchester has emerging or established strengths, like advanced materials, artificial intelligence and diagnostics.

We look forward to working with partners to ensure this funding supports the growth of our future industries and delivers greater prosperity for our people.

Hi lohmaikai,
20 minutes into our 21st November 2022 Presentation David Budd did say that GDR are working with Independent Economic Modellers to develop a 'Spread sheet' or a 'straight forward analysis tool' that can illustrate very effectively the net savings to a Hospital, or a Hospital system or the NHS as a whole!!
Note this Presentation can be found in the Genedrive PLC website.

I do not believe that Riverfort have agreed this financing with the view of just getting their money back? - This would make no sense at all. I believe Riverfort believe they will at least double their investment here i.e. a minimum share price of 64p incoming.
I am not sure whether Riverport have received a better detailed explanation view of what we have to come, or that Riverfort can see the benefits of what is to come, from the same information we have?!

AIHL:-
. A First in the World Hearing Loss Test.
. NICE Recommendation.
. Increased Roll out in the UK
. UK market potential of £8.5 million per annum
. Increasing Distributer agreements in Europe.
. Europe market potential of £35 million per annum
. USA market potential of £35 million per annum

CYP2C19
. Possible DEVOTE Finance in coming
. UK market potential of £8.5 million per annum
. Europe market potential of £90 million per annum
. USA market potential of £60 million per annum

Finance:-
. Financed until at least June 2024, should this finance be required?
. Expected self sufficient Revenue by June 2024!
. Expected saving to the NHS on full adoption of just the AIHL Test £5.8 million per year.
. There are currently no open short positions in Genedrive.

MASSIVE LIFE BENEFITS TO PATIENTS !!!!

I can see 13 messages and 6 Trades.

In the Header of the RNS:-

''£5 million Equity Prepayment Facility in place with initial draw down of £2 million''

£2 million Draw down this week - And a vote by Share Holders to accept the remaining £3 million facility should we want too!!!

Hi stephen11,
Just catching up on this afternoon/evening posts - it was a pleasure to read your earlier post!!!
Looking forward to our future, and our patience paying off !!!

I am pleased to confirm our ''GDR SPACEX'' Rocket is well maintained, and Full of High Quality Fuel - Ready for Launch !!!!

This a Master stroke by our GDR - Ian Gillham; David Budd; Russ Shaw - Brilliant- Well Done!!!
They said they are looking at alternative methods to a Share Placing, and also mentioned Grant applications, and Cost savings to reduce cash runaway - They are Good to their word !!!
They also said they have a Good record in raising funds, and they are certainly right about this too!!

I have always believed in our BOD's, and have said how much I admire them - Looking forward to our Patience paying off, over the coming Days; Weeks and Months !!!!

With our Funding situation addressed, our future looks Assured and Stable - Just as it should, with our Excellent Products, including ''First In the World'' Status !!!

Very Pleased!!!